NAVCO Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
NAVCO Pharmaceuticals's earnings have been declining at an average annual rate of -20.2%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 114.1% per year.
Key information
-20.2%
Earnings growth rate
-2.0%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | -114.1% |
| Return on equity | 2,461.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How NAVCO Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | 0 | 1 | 0 |
| 31 Mar 24 | 0 | -3 | 2 | 0 |
| 31 Dec 23 | 0 | -2 | 2 | 0 |
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Jun 23 | 0 | -4 | 1 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Sep 21 | 0 | -1 | 0 | 0 |
Quality Earnings: NAV has a high level of non-cash earnings.
Growing Profit Margin: NAV became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NAV has become profitable over the past 5 years.
Accelerating Growth: NAV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NAV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: Whilst NAV's Return on Equity (2460.98%) is outstanding, this metric is skewed due to their high level of debt.